Murex challenges Chiron's monopoly
This article was originally published in Clinica
Chiron has re-amended its UK HCV patent by deleting claims covering non-HCV products, thereby validating the patent. The UK Court of Appeals had found on November 2nd that the patent was only partially valid but at the hearing on November 7th to address outstanding hepatitis C patent litigation issues (see Clinica No 679, p 12), the Court allowed Chiron to re-amend the patent. As a result, the Court ruled that Murex and UBI still infringe the re-amended patent and a damage enquiry will follow.